Source: http://www.iprsonline.org/submissions/convention.htm
Timestamp: 2018-01-21 04:31:48
Document Index: 305467342

Matched Legal Cases: ['Sui generis', 'sui generis', 'sui generis', 'sui generis', 'sui generis', 'Sui generis', 'sui generis', 'art 15', 'Art 64', 'art 7', 'arts 7', 'sui generis', 'sui generis', 'art. 16', 'Sui generis', 'Sui generis', 'Sui generis', 'Art 7', 'art.15', 'art.64', 'Art 23', 'Art.66', 'Art 27', 'sui generis', 'art 15', 'sui generis', 'sui generis']

IPRsonline.org
Official Submissions to the WTO
Available at the WTO Document Search Facility
Article 27.3(b) | Public Health | Traditional Knowledge | Geographical Indications | Convention on Biological Diversity | Technology Transfer | Article 71.1 | Non-violation | International Organisations
Review of Article 27.3(b) of the TRIPS Agreement, and the relationship between the TRIPS Agreement and the Convention on Biological Diversity (CBD) and the protection of traditional knowledge and folklore - "A Concept Paper".
IP/C/W/383
Brazil on behalf of the delegations of China, Cuba, Dominican Republic, Ecuador, India, Pakistan, Thailand, Venezuela, Zambia and Zimbabwe
Council for Trade-Related Aspects of Intellectual Property Rights - The relationship between the TRIPS Agreement and the CBD and the protection of traditional knowledge.
Summary. A. Introduction. B. Relevant provisions in the CBD. C. The relationship between the TRIPS Agreement and the CBD. D. Proposal.
IP/C/W/356
Review of Article 27.3(b).
IP/C/W/310
Council for Trade-Related Aspects of Intellectual Property Rights - Review of article 27.3(b) of the TRIPS agreement: the relationship between the TRIPS agreement and the Convention on Biological Diversity
TRIPS/CBD: interaction but no legal conflict. Developed countries should provide technological assistance to developing countries. Benefit-sharing system should be established. Sui generis should be flexible. Consider disclosure of origin provision for TRIPS.
IP/C/W/293
Council for Trade-Related Aspects of Intellectual Property Rights - Review of article 27.3(b): the view of Switzerland
Review to focus on scope of patentability and sui generis. Biotechnology should be patent-protected. 27.3(b) is balanced. UPOV is in foreground as sui generis. Breeders exemption and Farmers privilege important. CBD/27.3(b) mutually supportive.
IP/C/W/284
Council for Trade-Related Aspects of Intellectual Property Rights - Review of the provisions of article 27.3(b) of the TRIPS agreement
Concerns of developing Members may be dealt with outside 27.3(b) review. Need to: develop other instruments to address concerns; provide technological assistance on CBD implementation; negotiate measures in WIPO and (if necessary) TRIPS on benefit-sharing etc.
IP/C/W/254
Council for Trade-Related Aspects of Intellectual Property Rights - Views of the United States on the Relationship between the Convention on Biological Diversity and the TRIPS Agreement
TRIPS provisions support measures that would implement CBD.
IP/C/W/257
Council for Trade-Related Aspects of Intellectual Property Rights - Review of the Provisions of Article 27.3(b) - Japan's View
27.3(b) review is limited to the 'optional exclusion' and 'exceptional exclusion'. 27.3(b) and development; definition of micro-organisms, 'inventions' and 'discoveries'; sui generis and UPOV; ethical issues; TRIPS/CBD, disclosure of origin, benefit-sharing; TK and farmers' rights.
IP/C/W/236
Council for Trade-Related Aspects of Intellectual Property Rights - Review of article 27.3(b)
Scope of review needs clarifying. 27.3(b)/development merits discussion. Members should retain flexibility to exclude plant/animal patents. Need precise definition of 'micro-organism'. Members should preserve flexibility on sui generis. 27.3(b) review must include ethical concerns about lifeforms patents. TRIPS/CBD should be supportive. So amend 27.3(b) to include disclosure of origin, TK used, evidence of benefit-sharing and prior-informed consent from government or community.
IP/C/W/228
Council for Trade-Related Aspects of Intellectual Property Rights - Review of the provisions of article 27.3(b). Further views of the United States.
Definition of 'micro-organisms'. Sui generis PVP. Ethical considerations. TK. CBD / TRIPS compatibility. Access to genetic resources and benefit-sharing.
IP/C/W/209
Committee on Trade and Environment - Council for Trade-Related Aspects of Intellectual Property Rights - Protection of Biodiversity and Traditional Knowledge - The Indian Experience
Introduction. The Biological Diversity Bill 2000. TRIPs, biodiversity and patent issues. Protection of traditional knowledge associated with biological resources: Suggestions/options for protecting traditional knowledge: Documentation of traditional knowledge. Traditional Knowledge Digital Library. Registration and innovation patent system. Development of a sui generis system. Some other aspects. Provisions in the Biodiversity Bill 2000 and Patents (Second Amendment) Bill 1999. International action.
IP/C/W/198
Council for Trade-Related Aspects of Intellectual Property Rights - (Communication from India)
Incorporate in TRIPS a provision that patents incompatible with CBD art 15 must not be granted. Art 64, paragraph 2 must be modified to clarify that subparagraphs b and c of GATT '94 shall not apply to TRIPS. Operationalise TRIPS art 7 and 8 by providing technological transfer.
IP/C/W/196
Council for Trade-Related Aspects of Intellectual Property Rights - Proposals on Intellectual Property Rights Issues
Review TRIPS to consider operationalising arts 7 and 8 technological transfer. TRIPS/CBD relationship and national law.
IP/C/W/195
Argentina, Costa Rica, Kenya and United Kingdom
Council for Trade-Related Aspects of Intellectual Property Rights - The Relationship Between the Convention on Biological Diversity (CBD) and the Agreement on the Trade-Related Aspects of Intellectual Property Rights (TRIPS); With a Focus on Article 27.3(B) - Background Note by the Secretariat
Plant variety protection - Relevant international instruments. Information provided to the TRIPS Council on the Implementation of Article 27.3(B). Country studies on sui generis systems based on the UPOV model. Legislation enacted to give effect to the CBD. Annex 1: Synoptic table of plant variety protection systems.
IP/C/W/175
Kenya, on behalf of the African Group
Council for Trade-Related Aspects of Intellectual Property Rights - Review of the provisions of article 27.3(b)
Clarify scope of review. Extend implementation deadline till after Review. Clarify why exclusion does not extend to 'micro-organisms' and 'micro-biological processes'. Add interpretative footnote re sui generis confirming can include protection of indigenous and local community innovations; right to save and exchange seeds and sell harvest; prevent anti-competitive rights or practices threatening food security. Harmonise 27.3(b) and CBD.
IP/C/W/163
TRIPS and CBD should be mutually supportive. Note CBD art. 16.5. Need to consider benefit-sharing and ethics of patents on lifeforms. Should not alter delicate 27.3(b) wording. Consider disclosure of origin proposal. Sui generis should be flexible.
IP/C/W/167
US view of 27.3(b). Life form patentability, and benefits of this. Ethical questions. Sui generis protection. TRIPS and CBD. Protection for genetic resources and TK.
IP/C/W/162
Lifeform patentability. TRIPS and CBD. Contracts an insufficient solution for TK protection. Sui generis protection.
IP/C/W/164
Cuba, Dominican Republic, Egypt, El Salvador, Honduras, India, Indonesia, Malaysia, Nigeria, Pakistan, Sri Lanka and Uganda
General Council - Preparation for the 1999 Ministerial Conference - Implementation Issues to be Addressed in the First Year of Negotiations
Art 7 and 8 to be operationalised to promote technological transfer. Amend 27.3(b) in light of CBD and IU. 27.3(b) review to clarify artificial distinction between 'biological' and 'micro-biological' organisms and processes; ensure right to save and exchange seeds and sell harvest; prevent anti-competitive practices threatening food security.
General Council - Preparation for the 1999 Ministerial Conference - Implementation Issues to be Addressed Before/At Seattle
Pending examination of TRIPS/CBD relationship, patents incompatible with CBD art.15 will not be granted. TRIPS art.64, paragraph 2, will be modified so that subparagraph b and c of GATT 94 Art 23 shall not apply. Art.66.2 provisions shall be made obligatory and subject to periodic notification. Guidelines on categories of incentives shall be established. Art 27.3(b) implementation shall be 5 years from end of Review. List of 27.3b exceptions to patentability shall include drugs on WHO essential drugs list.
WT/GC/W/354
Southern African Development Community (SADC), SADC Ministers' Agreed Negotiating Objectives for the Third WTO Ministerial Conference
Members should retain flexibility and options for PVP, including sui generis. Review should seek to harmonise 27.3(b) and CBD. Microbiological processes could also be excluded from patentability.
WT/L/317
Bangladesh (LDCs)
General Council - The Challenge of Integrating LDCS into the Multilateral Trading System - Coordinating Workshop for Senior Advisers to Ministers of Trade in LDCs in Preparation for the Third WTO Ministerial Conference
Should be formal clarification that naturally-occurring plants and animals, their parts, gene sequences and essentially biological processes for production should not be granted patents. Patents inconsistent with CBD art 15 must not be granted. Members should retain flexibility re sui generis systems.
WT/GC/W/251
General Council - Preparations for the 1999 Ministerial Conference - Contribution to the Preparatory Process
Different interpretations of 27.3(b) exist, especially re sui generis. 27.3(b) should be amended to protect TK and farmers' rights. CBD and TRIPS should be harmonised.
WT/GC/W/233
General Council - Preparations for the 1999 Ministerial Conference - General Council Discussion on the Built-In-Agenda 23-24 November 1998
Patentable subject matter remains difficult issue, so status quo should not be altered at this stage. Need to examine TRIPS and CBD relationship.
WT/GC/W/136